These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 6895786)

  • 21. Treatment of renal osteodystrophy with 1alpha-hydroxycholecalciferol (1alpha-OH-D3) in conjunction with a high dialysate calcium.
    Winney RJ; Bone JM; Anderson TJ; Robson JS
    Calcif Tissue Res; 1977 May; 22 Suppl():94-100. PubMed ID: 912593
    [No Abstract]   [Full Text] [Related]  

  • 22. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
    Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
    Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease.
    Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; de Luca HF
    Proc Eur Dial Transplant Assoc; 1976; 12():227-36. PubMed ID: 935115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effects of 1 alpha-(OH)D3 on renal osteodystrophy--a 5-year retrospective evaluation].
    Kakuhara T; Mizoguchi M; Itoh M; Nagasawa M; Mori T; Ohtsuka K; Kubota M; Minatoguchi T; Ohara K; Yoshida M; Koide H; Ohno J
    Nihon Jinzo Gakkai Shi; 1982 Jun; 24(6):693-704. PubMed ID: 7176180
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization.
    Fournier A; Bordier P; Gueris J; Sebert JL; Marie P; Ferrière C; Bedrossian J; DeLuca HF
    Kidney Int; 1979 Feb; 15(2):196-204. PubMed ID: 513484
    [No Abstract]   [Full Text] [Related]  

  • 26. Calcitriol oral pulse therapy in children with renal osteodystrophy.
    Cano F; Delucchi A; Wolff E; Rodriguez E; Fuentes A
    Pediatr Nephrol; 1995 Oct; 9(5):606-8. PubMed ID: 8580020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement of early renal bone disease with alfacalcidol therapy.
    CMAJ; 1995 Nov; 153(10):1470, 1472. PubMed ID: 7585375
    [No Abstract]   [Full Text] [Related]  

  • 28. [Hydroxylated metabolites of vitamin D. Therapeutic use of calcitriol and dihydrotachysterol].
    Stĕpán J; Lachmanová J; Wilczek H; Straková M; Zichová M; Horn V; Tomásek R; Pacovský V
    Cas Lek Cesk; 1985 Dec; 124(50):1550-6. PubMed ID: 3841297
    [No Abstract]   [Full Text] [Related]  

  • 29. [Therapeutic indications obtained from short- and medium-term biohumoral changes after parathyroidectomy].
    Sforzini S; Viganò MR; Rosa M; Redaelli B
    Minerva Med; 1985 Mar; 76(9-10):393-6. PubMed ID: 3982696
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.
    Muirhead N; Catto GR; Edward N; Fraser RA; O'Riordan JL; Papapoulos SE; Adami S
    Proc Eur Dial Transplant Assoc; 1980; 17():543-7. PubMed ID: 6972529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prevention and treatment of renal osteodystrophy: present and future].
    Fernández E; Craver L
    Nefrologia; 2006; 26 Suppl 3():19-27. PubMed ID: 17469423
    [No Abstract]   [Full Text] [Related]  

  • 32. Regression of massive tumoral calcinosis of the ischium in a dialysis patient after treatment with reduced calcium dialysate and i.v. administration.
    Apostolou T; Tziamalis M; Christodoulidou C; Fountas P; Billis A
    Clin Nephrol; 1998 Oct; 50(4):247-51. PubMed ID: 9799070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 1alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in renal bone disease.
    Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; De Luca HF
    Calcif Tissue Res; 1976 Aug; 21 Suppl():226-35. PubMed ID: 782662
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure.
    Henderson RG; Russell RG; Ledingham JG; Smith R; Oliver DO; Walton RJ; Small DG; Preston C; Warner GT
    Lancet; 1974 Mar; 1(7854):379-84. PubMed ID: 4131033
    [No Abstract]   [Full Text] [Related]  

  • 35. A possible role for propranolol in the treatment of renal osteodystrophy.
    Caro JF; Besarab A; Burke JF; Glennon JA
    Lancet; 1978 Aug; 2(8087):451-4. PubMed ID: 79809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PTH and bone markers of renal osteodystrophy in predialysis chronic renal failure.
    Coen G; Mazzaferro S; Ballanti P; Bonucci E
    J Endocrinol Invest; 1992; 15(9 Suppl 6):129-33. PubMed ID: 1300330
    [No Abstract]   [Full Text] [Related]  

  • 37. Osteodystrophy of dialysed patients treated with vitamin D.
    Verberckmoes R; Bouillon R; Krempien B
    Proc Eur Dial Transplant Assoc; 1973; 10(0):217-26. PubMed ID: 4370246
    [No Abstract]   [Full Text] [Related]  

  • 38. Questions on the use of vitamin D3.
    Balsan S; Steendijk R
    Pediatrics; 1980 Sep; 66(3):483-4. PubMed ID: 7422447
    [No Abstract]   [Full Text] [Related]  

  • 39. [Management of renal osteopathy in patients with chronic dialysis].
    Kiss D; Brunner FP
    Schweiz Med Wochenschr; 1996 Oct; 126(42):1792-8. PubMed ID: 8966512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
    Moe S; Wazny LD; Martin JE
    Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.